0000874015-17-000074.txt : 20171219 0000874015-17-000074.hdr.sgml : 20171219 20171219202757 ACCESSION NUMBER: 0000874015-17-000074 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171215 FILED AS OF DATE: 20171219 DATE AS OF CHANGE: 20171219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KLEIN JOSEPH III CENTRAL INDEX KEY: 0001206369 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 171265512 MAIL ADDRESS: STREET 1: C/O GENAISSANCE PHARMACEUTICALS INC STREET 2: FIVE SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2017-12-15 0000874015 IONIS PHARMACEUTICALS INC IONS 0001206369 KLEIN JOSEPH III C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT CARLSBAD CA 92010 1 0 0 0 Common Stock 2017-12-15 2017-12-15 4 M 0 3000 28.47 A 12939 D Common Stock 2017-12-15 2017-12-15 4 S 0 3000 51.69 D 9939 D Common Stock 100 I By son NonEmployee Director stock option (right to buy) 28.47 2017-12-15 2017-12-15 4 M 0 3000 0 D 2017-07-01 2023-06-30 Common Stock 3000 3000 D Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.135 to $52.060, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. /s/B. Lynne Parshall, attorney-in-fact 2017-12-18